Figure 1S. Study participants disposition and missing data.

710 AIIRD patients vaccinated with 2 doses of BNT162b2 were recruited: 471 from TLVMC 162 from Carmel MC Disease activity scores: 77 from Hadassah MC RA-CDAI: Pre-vaccine: data were available for 190 out of 263 pts 125 non-AIIRD controls vaccinated with Post-vaccine: data were available for 197 2 doses of BNT162b2 were recruited: out of 263 pts RA-SDAI: Pre-vaccine: data were available for 177 out of 263 pts 38 from TLVMC Post-vaccine: data were available for 178 out of 263 pts 62 from Carmel MC RA-DAS28-CRP: Pre and post-vaccine: data were available for 176 out of 263 pts 24 AIIRD patients (3 25 from Hadassah MC PsA-CDAI: Pre-vaccine: data were available from TLVMC, 21 from for 124 out of 165 pts CMC) and 5 non-AIIRD Post-vaccine: data were available for 132 out of 165 pts controls (from C MC) PsA-DAPSA: Pre and post-vaccine: data were excluded due to were available for 125 out of 165 pts lack of serology test PsA-PASI: Pre vaccine: data were available for 138 out of 165 pts result until study closure Post-vaccine: data were available for 142 686 AIIRD patients out of 165 pts AxSpA-ASDAS: Pre vaccine: data were 121 controls available for 48 out of 68 pts Post-vaccine: data were available for 52 out Had a serology test result and were of 68 pts included in the primary endpoint AxSpA-BASDAI: Pre-vaccine: data were analysis. available for 52 out of 68 pts All patients had demographic and Post-vaccine: data were available for 58 out medication data. SLE-SLEDAI: Pre-vaccine: data were available for 94 out of 101 pts Post-vaccine: data were available for 87 out Influenza vaccine: data were Adverse events after the 1st of 101 pts not reported for 13 controls Vasculitis-PGA: Pre –vaccine: data were dose of vaccine: data were not from CMC and for 13 AIIRD available for 66 out of 70 pts reported for 13 AIIRD patients (6 Post-vaccine: data were available for 64 out patients (7 from TLVMC, 4 from from TLVMC and 7 from CMC). CMC and 2 from HMC). Vasculitis-PhGA: Pre and post-vaccine data were available for 64 out of 70 pts Adverse events after the 2nd Influenza vaccine date: data IIM-PGA: Pre-vaccine: data were available dose of vaccine: data were not for all pts were not available for 44 out of reported for 16 AIIRD patients (7 Post-vaccine: data were available for 17 out 89 controls, and 198 out of 542 of 19 pts from TLVMC and 9 from CMC). AIIRD patients that were IIM-PhGA: Pre-vaccine: data were available for 18 out of 19 pts vaccinated. Post-vaccine: data were available for 17 out of 19 pts

<u>Rituximab dose:</u> data were not available for 2 out of 86 patients treated with rituximab: *1 from TLVMC*, and *1 from HMC* 

Legend: AlIRD, autoimmune inflammatory rheumatic diseases; TLVMC, Tel-Aviv Medical Center; MC, medical center; CMC, Carmel Medical Center; HMC, Hadassah Medical Center; RA, rheumatoid arthritis; CDAI, clinical disease activity index; SDAI, simplified disease activity index; DAS28-CRP, disease activity score28-CRP; PsA, psoriatic arthritis; DAPSA, disease activity psoriatic arthritis; PASI, psoriasis area severity index; AxSpA, axial spondyloarthritis; ASDAS, ankylosing spondylitis disease activity score; BASDAI, Bath ankylosing spondylitis disease activity index; SLE, systemic lupus erythematosus; SLEDAI, systemic lupus erythematosus disease activity index; PGA, patient global assessment; PhGA, physician global assessment; IIM, idiopathic inflammatory myositis.